The hard work of building businesses is what drives returns for investors, but maximising value also means buying well and selling well. As your advisers, we can make a big difference to the outcome.

Our deep sector knowledge and long-established international network mean we can offer insights on industry trends, strategic positioning and competitive intelligence that give us an edge over generalist advisers. This specialism is allied to buy-side and sell-side M&A expertise across the full range of deal structures – from growth capital to minority stake sales, buy-outs and strategic exits.

Whether you are a venture capital provider, buyout fund, family office or infrastructure investor, we understand your objectives and have the capability to help you achieve them.

Crucially, we work together as one-team. We collaborate and work with partners, and our carefully nurtured internal culture permeates through the whole organisation. As Managing Partner, Julie Langley puts it, “For Results, every deal is important to everybody in our firm.”

Deals are incredibly complex and never straightforward, but we never give up once we are on board. 100 per cent of the deals we’ve closed are referenceable from our past clients.

Mark Williams



We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.


When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.


With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.


We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Apr 2022
has received investment from
and EnBW New Ventures, with follow-on investment from ETF Partners
Apr 2022
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF
Apr 2022
has been acquired by
Mar 2022
An AlbionVC-backed company
has received investment from
Morgan Stanley Expansion Capital and Keyhaven Capital Partners co-invest
Mar 2022
has received investment from
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Feb 2022
has received investment from
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to

Results. Great people creating great outcomes, together.

Latest Insights

24th May 2022

Crossrail opens – a big day for travellers to and workers in London

At Results Healthcare we execute transactions around the world, with active projects in North America, Europe and Asia Pacific, so we see ourselves as a global organisation with offices and employees in London and New York, so a blog on transport in London might seem oddly parochial, but the opening of Crossrail, or the Elizabeth […]

4th May 2022

The Technology Services Perspective – Q1 2022

Deal activity for Q1 2022 has increased 30% over the previous quarter, to a total of 237 transactions. Transactions have mainly focused on strategic tuck-ins that are centred around acquiring next-gen and nearshore capabilities, such as robotic process automation, customer experience consultancy and influencer-based social media marketing. Even in the current macro environment, March showed […]

4th May 2022

The CyberScope – Q1 2022

Despite a backdrop of some macroeconomic uncertainty, the first quarter of 2022 started strong with 52 M&A transactions, representing a 41% increase from Q1 last year, as the security sector again proves its strong resilience. Google’s $5.4Bn acquisition of cloud and managed cybersecurity provider, Mandiant, very clearly demonstrated the opening of a new front in […]